investiment.io
Avadel Pharmaceuticals plc
$13.92
0.68 (5.14%)
Avadel Pharmaceuticals plc
$13.92
0.68 (5.14%)
AVDL Price Chart
| Basic | |
|---|---|
| Market Cap | $1.21B |
| Price | $13.2 |
| 52 Week Range | 9.5-19.09 |
| Beta | 1.63 |
| Margins | |
| Gross Profit Margin | 94.62% |
| Operating Profit Margin | -103.82% |
| Net Profit Margin | -111.64% |
| Valuation (TTM) | |
| P/E Ratio | -12.60 |
| Price to Sales Ratio | 14.08 |
| Price to Book Ratio | 19.04 |
| PEG Ratio | -0.34 |
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Full-Time Employees
154
Website
IPO Date
1996-06-07T00:00:00.000Z
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Phone
353 1 901 5201
Address
10 Earlsfort Terrace, Dublin, 2, IE
CIK
0001012477